Positron emission tomography/magnetic resonance imaging with68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?-Reference-Cited by-同舟云学术

Positron emission tomography/magnetic resonance imaging with68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?

Published:2014-07-21 Issue:12 Volume:21 Page:1286-1288
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J Urol

Author:

Maurer Tobias¹,Beer Ambros J²,Wester Hans-Jürgen³,Kübler Hubert¹,Schwaiger Markus²,Eiber Matthias²⁴

Affiliation:

1. Department of Urology; Technical University of Munich, Klinikum rechts der Isar; Munich Germany

2. Department of Nuclear Medicine; Technical University of Munich, Klinikum rechts der Isar; Munich Germany

3. Institute of Pharmaceutical Radiochemistry; Technical University of Munich, Klinikum rechts der Isar; Munich Germany

4. Institute of Diagnostic and Interventional Radiology; Technical University of Munich, Klinikum rechts der Isar; Munich Germany

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.12577/fullpdf

Reference7 articles.

1. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis;Umbehr;Eur. Urol.,2013

2. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer;Schafer;EJNMMI Res.,2012

3. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH;Afshar-Oromieh;Eur. J. Nucl. Med. Mol. Imaging,2012

4. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results;Roethke;Eur. Urol.,2013

5. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses;Drzezga;J. Nucl. Med.,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and survival outcomes in patients with a high PSA and non-metastatic prostate cancer;Journal of the Formosan Medical Association;2022-01

2. PET/MR for evaluation of musculoskeletal malignancies;Clinical and Translational Imaging;2021-11-05

3. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial;BMC Cancer;2018-04-02

4. 68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost;European Journal of Nuclear Medicine and Molecular Imaging;2018-02-21

5. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer;Nuclear Medicine Communications;2017-12